DUSP6 and non-small cell lung carcinoma: Moreover, we found that overexpression of DUSP6 showed a synergistic anti-viability effect with osimertinib in NSCLC cells, but DUSP6 M62I mutation significantly decreased the cellular osimertinib sensitivity.